Drug-induced rhabdomyolysis (DIR) as one of the major forms of rhabdomyolysis is of an Idiosyncratic nature and thus difficult to study. To our knowledge, few cases of DIR are available, and they are scattered in different kinds of literature, electronic medical records, and pharmacovigilance database, resulting in the lurch of the progress of early prevention and predictive model development. Now, the information including DIR classification, post-marketing DIR surveillance data and drug properties is centralized and managed under our web-based application named Drug-induced Rhabdomyolysis Atlas (DIRA). The utility of DIRA was exemplified with some key aspects of idiosyncratic adverse drug reaction (IADR) management including precision dosing, concomitant use of drugs, and predictive model development.
Wen Z, Liang Y, Hao Y, Delavan B, Huang R, Mikailov M, Tong W, Li M, Liu Z.
Drug Discov Today. 2019, 24(1), 9-15. https://doi.org/10.1016/j.drudis.2018.06.006.
The content of this database of rhabdomyolysis is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
The views presented in this website do not necessarily reflect current or future opinion or policy of the US Food and Drug Administration. Any mention of commercial products is for clarification and not intended as endorsement.